Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2013

View Archived Issues

Pfizer discloses fourth-quarter and full-year 2012 results

Adamed presents new series of agents for CNS disorders

Vaxart describes avian influenza adenovirus-based vaccine and double-stranded RNA adjuvant

Researchers engineer synthetic biomarkers for urinary monitoring

Chugai provides update on pipeline along with 2012 financial results

Glucose lowered equally with mitoglitazone and pioglitazone in diabetes trial

New STEP inhibitors designed at Otsuka

New recombinant head shock proteins developed at Alternative Innovative Technologies

New MAbs described by Oxford BioTherapeutics

New anti-properdin antibodies developed at the University of Pennsylvania

Polymorphism in the ANGPT1 gene as predictor of increased mortality in septic shock patients

Svelte Medical Systems treats first patient in the DIRECT II stent study

Study of tasimelteon in MDD fails to meet endpoint

Italian hospital to conduct phase I/II trial of DPX-0907

Celsion reports results from the phase III HEAT study of ThermoDox

Ezose Sciences enters glycomics research agreement

Phylogica receives milestone payment under collaboration with Janssen Biotech

First patient enrolled in phase III tivantinib trial

Pharmaxis provides update on Bronchitol

A novel synthetic cofactor of glyoxalase prevents long-term cognitive impairment in vivo

Galectin Therapeutics files IND for phase I studies of GR-MD-02

Targovax includes first patient in phase I/II TG-01 study

Mobile ELISA device allows disease testing and transmission of results

OncoEthix studies OTX-015 in patients with hematologic malignancies

Committee recommends completion of phase IIb tamibarotene trial

FDA issues approval letter regarding expanded Corifact indication